• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Executive Officer Hsieh Ming covered exercise/tax liability with 5,060 shares, decreasing direct ownership by 0.62% to 810,679 units (SEC Form 4)

    5/28/25 4:16:32 PM ET
    $FLGT
    Medical Specialities
    Health Care
    Get the next $FLGT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hsieh Ming

    (Last) (First) (Middle)
    C/O FULGENT GENETICS, INC.
    4399 SANTA ANITA AVENUE

    (Street)
    EL MONTE CA 91731

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Fulgent Genetics, Inc. [ FLGT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    05/23/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 05/23/2025 F 2,116(1) D $20.31 813,623 D
    Common Stock 05/26/2025 F 2,944(2) D $20.31 810,679 D
    Common Stock 220,816 I By Trust(3)
    Common Stock 7,895,115 I By Trust(4)
    Common Stock 1,000 I Uniform Transfer to Minor Account(5)
    Common Stock 1,000 I Uniform Transfer to Minor Account(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023.
    2. The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.
    3. Securities held by the Dynasty Trust. Mr. Hsieh is the grantor of the Dynasty Trust and he and his spouse, Eva Hsieh, and Jian Xie serve on the investment committee of the Dynasty Trust. Mr. Hsieh disclaims any beneficial interest except with respect to any pecuniary interest therein.
    4. Securities held by The Ming Hsieh Trust (the "Hsieh Trust"). Mr. Hsieh is the trustee of the Hsieh Trust and possesses the sole voting and dispositive power with respect to securities held by the Hsieh Trust.
    5. Shares held in a Uniform Transfers to Minor Act account for which Ming Hsieh acts as custodian and possesses the sole voting and dispositive power.
    /s/ Paul Kim as Attorney-in-Fact 05/28/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $FLGT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FLGT

    DatePrice TargetRatingAnalyst
    8/5/2025$30.00Neutral → Buy
    UBS
    12/7/2023$35.00Neutral
    UBS
    12/8/2022$65.00 → $40.00Overweight → Neutral
    Piper Sandler
    11/18/2022$45.00Outperform
    Raymond James
    8/25/2022$65.00Outperform
    Credit Suisse
    2/4/2022$80.00Overweight
    Piper Sandler
    1/25/2022$141.00 → $125.00Outperform
    Oppenheimer
    8/10/2021$55.00 → $65.00Underperform
    Credit Suisse
    More analyst ratings

    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fulgent Reports Second Quarter 2025 Financial Results

    Core Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of $34.4 million, or GAAP gross margin of 42.1%; Non-GAAP gross profit of $36.2 million, or Non-GAAP gross margin of 44.2% GAAP loss of $19.0 million, or ($0.62) per share, inclusive of a one-time charge; Non-GAAP income of $2.1 million, or $0.07 per share Ended second quarter with $777.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic

    8/1/25 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced it has received CE certification under the European Union (EU)'s In Vitro Diagnostic Regulation (EU) 2017/746 (IVDR) for its germline next-generation sequencing (NGS) system, which includes FulgentExome and Fulgent Pipeline Manager (PLM). Based on available information, Fulgent may be the first laboratory to receive CE mark for one of the most comprehensive end-to-end germline testing offerings, with more than 4600 genes validated for diagnostic use. FulgentExome is a patient-centric, phe

    7/17/25 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent

    7/10/25 4:05:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    SEC Filings

    View All

    SEC Form 10-Q filed by Fulgent Genetics Inc.

    10-Q - Fulgent Genetics, Inc. (0001674930) (Filer)

    8/1/25 7:09:52 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Fulgent Genetics, Inc. (0001674930) (Filer)

    8/1/25 7:05:22 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulgent Genetics Inc.

    SCHEDULE 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    7/29/25 5:04:32 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Kim Paul bought $1,596,470 worth of shares (100,000 units at $15.96), increasing direct ownership by 40% to 348,282 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    3/5/25 6:47:40 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Hsieh Ming covered exercise/tax liability with 1,339 shares, decreasing direct ownership by 0.17% to 809,340 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    8/5/25 4:56:56 PM ET
    $FLGT
    Medical Specialities
    Health Care

    CFO and Treasurer Kim Paul covered exercise/tax liability with 2,743 shares, decreasing direct ownership by 0.80% to 339,828 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    7/29/25 6:04:47 PM ET
    $FLGT
    Medical Specialities
    Health Care

    President and COO Xie Jian covered exercise/tax liability with 4,352 shares, decreasing direct ownership by 1% to 367,144 units (SEC Form 4)

    4 - Fulgent Genetics, Inc. (0001674930) (Issuer)

    7/29/25 6:04:27 PM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fulgent Genetics upgraded by UBS with a new price target

    UBS upgraded Fulgent Genetics from Neutral to Buy and set a new price target of $30.00

    8/5/25 7:03:39 AM ET
    $FLGT
    Medical Specialities
    Health Care

    UBS initiated coverage on Fulgent Genetics with a new price target

    UBS initiated coverage of Fulgent Genetics with a rating of Neutral and set a new price target of $35.00

    12/7/23 6:19:41 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Genetics downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Fulgent Genetics from Overweight to Neutral and set a new price target of $40.00 from $65.00 previously

    12/8/22 7:45:09 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

    SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    11/5/24 4:46:55 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/23/24 4:13:58 PM ET
    $FLGT
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Fulgent Genetics Inc. (Amendment)

    SC 13G/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    1/26/23 8:52:11 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Leadership Updates

    Live Leadership Updates

    View All

    DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

    3/7/25 6:19:00 PM ET
    $ALK
    $AMBC
    $ATI
    Air Freight/Delivery Services
    Consumer Discretionary
    Property-Casualty Insurers
    Finance

    Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing

    PRESS RELEASE - 10/06/2024, 07:00 CEST Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing Mechelen, Belgium 10 June 2024 – Biocartis NV (the ‘Company' or ‘Biocartis'), an innovative molecular diagnostics company, is pleased to announce the appointment of Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as Vice President Global Marketing. Gina Wallar, PhD as Chief Business Officer: Gina Wallar was appointed as Biocartis' Chief Business Officer on 15 April 2024 and will be responsible for Biocartis' business development and partnering initiatives, as well as US commercialization. Dr. Wallar has more than 20 year

    6/10/24 1:00:00 AM ET
    $FLGT
    $NEO
    Medical Specialities
    Health Care
    Precision Instruments

    Brixton Biosciences Announces $33M in Series B Funding to Advance Novel Technology for the Treatment of Pain

    After promising results from first-in-man studies with its novel Neural Ice™ technology, the Massachusetts-based company will use the capital to initiate pivotal clinical studies in both chronic and acute pain indications CAMBRIDGE, Mass., May 14, 2024 /PRNewswire/ -- Brixton Biosciences, a spin-out from Massachusetts General Brigham and a clinical stage life sciences company developing novel therapies for chronic and acute pain, today announced that it closed a Series B funding round of $33M. The round was led by Schooner Capital with notable participation by SV Health Investors, Sparta Group, Excelestar Ventures,  PV Capital Management, and Catalyst Health Ventures.

    5/14/24 9:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    $FLGT
    Financials

    Live finance-specific insights

    View All

    Fulgent Reports Second Quarter 2025 Financial Results

    Core Revenue of $81.7 million grows 16% year-over-year Raising Full Year 2025 Core Revenue Guidance to $320 million GAAP gross profit of $34.4 million, or GAAP gross margin of 42.1%; Non-GAAP gross profit of $36.2 million, or Non-GAAP gross margin of 44.2% GAAP loss of $19.0 million, or ($0.62) per share, inclusive of a one-time charge; Non-GAAP income of $2.1 million, or $0.07 per share Ended second quarter with $777.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic

    8/1/25 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025

    Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent" or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, 2025. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions. The call may be accessed through a live audio webcast on the Investor Relations section of the Company's website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location. About Fulgent Fulgent

    7/10/25 4:05:00 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Fulgent Reports First Quarter 2025 Financial Results

    Core Revenue of $73.5 million grows 16% year-over-year Reiterating Full Year 2025 Core Revenue Guidance of $310 million Non-GAAP income of $1.2 million, or $0.04 per share; GAAP loss of $11.5 million, or ($0.37) per share Ended Q1 with $814.6 million of cash, cash equivalents, restricted cash, and investments in marketable securities, representing cash per share of $26.60 Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2025. First Quarter 2025 Results: Total Revenue of $

    5/2/25 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care